Evidence map›Paper›PMID 39333867›Full record

ArticleBMC medical research methodology2024

Integrating randomized controlled trials and non-randomized studies of interventions to assess the effect of rare events: a Bayesian re-analysis of two meta-analyses.

Yun Zhou, Minghong Yao, Fan Mei, Yu Ma, Jiayidaer Huan, Kang Zou, Ling Li, Xin Sun

Abstract read
In one paragraph

Article in BMC medical research methodology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yun Zhou *Department of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China.
Minghong Yao *Department of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China.
Fan MeiDepartment of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China.
Yu MaDepartment of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China.
Jiayidaer HuanDepartment of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China.
Kang ZouDepartment of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China.
Ling LiDepartment of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China. liling@wchscu.cn.
Xin SunDepartment of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China, Center and MAGIC China Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, China. sunxin@wchscu.cn.

Funding

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University ZYGD23004National Natural Science Foundation of China 72204173, 82274368, and 71904134National Science Fund for Distinguished Young Scholars 82225049special fund for traditional Chinese medicine of Sichuan Provincial Administration of Traditional Chinese Medicine 2024zd023
6 · The paper itself

Abstract

backgroundThere is a growing trend to include non-randomised studies of interventions (NRSIs) in rare events meta-analyses of randomised controlled trials (RCTs) to complement the evidence from the latter. An important consideration when combining RCTs and NRSIs is how to address potential bias and down-weighting of NRSIs in the pooled estimates. The aim of this study is to explore the use of a power prior approach in a Bayesian framework for integrating RCTs and NRSIs to assess the effect of rare events.

methodsWe proposed a method of specifying the down-weighting factor based on judgments of the relative magnitude (no information, and low, moderate, serious and critical risk of bias) of the overall risk of bias for each NRSI using the ROBINS-I tool. The methods were illustrated using two meta-analyses, with particular interest in the risk of diabetic ketoacidosis (DKA) in patients using sodium/glucose cotransporter-2 (SGLT-2) inhibitors compared with active comparators, and the association between low-dose methotrexate exposure and melanoma.

resultsNo significant results were observed for these two analyses when the data from RCTs only were pooled (risk of DKA: OR = 0.82, 95% confidence interval (CI): 0.25-2.69; risk of melanoma: OR = 1.94, 95%CI: 0.72-5.27). When RCTs and NRSIs were directly combined without distinction in the same meta-analysis, both meta-analyses showed significant results (risk of DKA: OR = 1.50, 95%CI: 1.11-2.03; risk of melanoma: OR = 1.16, 95%CI: 1.08-1.24). Using Bayesian analysis to account for NRSI bias, there was a 90% probability of an increased risk of DKA in users receiving SGLT-2 inhibitors and an 91% probability of an increased risk of melanoma in patients using low-dose methotrexate.

conclusionsOur study showed that including NRSIs in a meta-analysis of RCTs for rare events could increase the certainty and comprehensiveness of the evidence. The estimates obtained from NRSIs are generally considered to be biased, and the possible influence of NRSIs on the certainty of the combined evidence needs to be carefully investigated.

Indexed as

Meta-Analysis as TopicRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsBayes TheoremDiabetic KetoacidosisHumansMelanomaMethotrexateMethotrexateSodium-Glucose Transporter 2 InhibitorsMeta-analysisNon-randomized studies of interventionsRare eventsRisk of bias

Identifiers

PMID39333867
PMCPMC11430109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.